PTOV1 antagonizes MED25 in RAR transcriptional activation

Biochemical and Biophysical Research Communications

Volumn 404, Issue 1, 2011, Pages 239-244

  Youn, Hye Sook ^a   Park, Ui Hyun ^a   Kim, Eun Joo ^b   Um, Soo Jong ^a  

^a Sejong University   (South Korea)

^b Dankook University   (South Korea)

Author keywords

Cancer; CBP; MED25; PTOV1; RA cytotoxicity; RAR

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; MED25 PROTEIN; PROSTATE TUMOR OVER EXPRESSED PROTEIN 1; PROTEIN; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CREB-BINDING PROTEIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDIATOR COMPLEX; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 78650893963     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.100     Document Type: Article

References (20)

1. De Luca L.M. Retinoids and their receptors in differentiation embryogenesis, and neoplasia. FASEB J. 1991, 5:2924-2933.
2. Chambon P. The molecular and genetic dissection of the retinoid signaling pathway. Recent Prog. Horm. Res. 1995, 50:317-332.
3. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996, 10:1031-1039.
4. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 2001, 1:181-193.
5. Freemantle S.J., Spinella M.J., Dmitrovsky E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene 2003, 22:7305-7315.
6. Mongan N.P., Gudas L.J. Diverse actions of retinoid receptors in cancer prevention and treatment. Differentiation 2007, 75:853-870.
7. Nettles K.W., Greene G.L. Ligand control of coregulator recruitment to nuclear receptors. Annu. Rev. Physiol. 2005, 67:309-333.
8. O'Malley B. The Year in Basic Science: nuclear receptors and coregulators. Mol. Endocrinol. 2008, 22:2751-2758.
9. Lee H.K., Park U.H., Kim E.J., Um S.J. MED25 is distinct from TRAP220/MED1 in cooperating with CBP for retinoid receptor activation. EMBO J. 2007, 26:3545-3557.
10. Benedit P., Paciucci R., Thomson T.M., Valeri M., Nadal M., Caceres C., de Torres I., Estivill X., Lozano J.J., Morote J., Reventós J. PTOV1, a novel protein overexpressed in prostate cancer containing a new class of protein homology blocks. Oncogene 2001, 20:1455-1464.
11. Wang C., McCarty I.M., Balazs L., Li Y., Steiner M.S. A prostate-derived cDNA that is mapped to human chromosome 19 encodes a novel protein. Biochem. Biophys. Res. Commun. 2002, 296:281-287.
12. Santamaria A., Fernandez P.L., Farre X., Benedit P., Reventos J., Morote J., Paciucci R., Thomson T.M. PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle. Am. J. Pathol. 2003, 162:897-905.
13. Santamaria A., Castellanos E., Gomez V., Benedit P., Renau-Piqueras J., Morote J., Reventós J., Thomson T.M., Paciucci R. PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts. Mol. Cell. Biol. 2005, 25:1900-1911.
14. Morote J., Fernandez S., Alana L., Iglesias C., Planas J., Reventos J., Ramón Y., Cajal S., Paciucci R., de Torres I.M. PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy. Clin. Cancer Res. 2008, 14:2617-2622.
15. Cho Y.S., Kim E.J., Park U.H., Sin H.S., Um S.J. Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor. J. Biol. Chem. 2006, 281:17588-17598.
16. Um S.J., Han H.S., Kwon Y.J., Park S.H., Rho Y.S., Sin H.S., Park J.S. Novel retinoic acid derivative ABPN has potent inhibitory activity on cell growth and apoptosis in cancer cells. Int. J. Cancer 2003, 107:1038-1046.
17. Han H.S., Kwon Y.J., Park S.H., Kim E.J., Rho Y.S., Sin H.S., Um S.J. Potent effect of 5-HPBR, a butanoate derivative of 4-HPR, on cell growth and apoptosis in cancer cells. Int. J. Cancer 2004, 109:58-64.
18. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 2002, 41:41-55.
19. Chakravarti D., LaMorte V.J., Nelson M.C., Nakajima T., Schulman I.G., Juguilon H., Montminy M., Evans R.M. Role of CBP/P300 in nuclear receptor signalling. Nature 1996, 383:99-103.
20. Kamei Y., Xu L., Heinzel T., Torchia J., Kurokawa R., Gloss B., Lin S.C., Heyman R.A., Rose D.W., Glass C.K., Rosenfeld M.G. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.